The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma

Image credit: JCO


KRAS gene mutations are found in 20-30% of non-small cell lung cancer (NSCLC), especially in adenocarcinoma. Compared to EGFR and ALK mutations, KRAS mutation in NSCLC may be associated with poorer prognosis. However, prognostic value of different KRAS mutation subtypes in NSCLC remains unknown. The goal of this study is to evaluate the association of KRAS mutation subtypes, PD-L1 expression and clinical outcome in patients diagnosed with primary lung adenocarcinoma.

Journal of Clinical Oncology
Yuan Du
Yuan Du
Senior Data Scientist

My interests include applied Statistics, Machine Learning, Deep Learning and Healthcare.